ST Lukes Regional Medical Center
ST Lukes Regional Medical Center was paid $942K by Medicaid between Jan 2018 and Nov 2024, across 108 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
MOUNTAIN HOME, ID 83647
Next to other Critical Access Hospital providers in Idaho
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,531 | $314K | |
| 2019 | 22,932 | $274K | |
| 2020 | 12,439 | $150K | |
| 2021 | 3,495 | $35K | |
| 2022 | 4,510 | $60K | |
| 2023 | 5,169 | $79K | |
| 2024incomplete | 2,220 | $29K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 1,311 | 1,125 | $149K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 578 | 548 | $96K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 1,103 | 941 | $94K |
| 80053 | Comprehensive metabolic panel | 5.9% | 7,008 | 5,907 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.4% | 8,739 | 7,132 | $51K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 738 | 574 | $35K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.4% | 422 | 393 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 511 | 482 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 559 | 500 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.1% | 559 | 500 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 1,221 | 965 | $20K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 142 | 114 | $18K |
96 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.7% | 1,215 | $16K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 230 | $15K |
| 81001 | 1.5% | 4,441 | $14K | |
| 84484 | 1.5% | 1,908 | $14K | |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 6,805 | $14K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 1,073 | $13K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.4% | 727 | $13K |
| 83690 | 1.3% | 1,869 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 1,812 | $12K |
| J7050 | Infusion, normal saline solution, 250 cc | 1.2% | 2,650 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.1% | 1,930 | $10K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 143 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 656 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,351 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,323 | $8K |
| 84702 | <1% | 455 | $7K | |
| 87081 | <1% | 942 | $6K | |
| 87077 | <1% | 745 | $6K | |
| 81025 | <1% | 856 | $6K | |
| 80061 | Lipid panel | <1% | 730 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 998 | $6K |
| 82962 | <1% | 3,767 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 274 | $6K |
| 83605 | <1% | 545 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 83 | $5K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 874 | $5K |
| 84439 | <1% | 651 | $5K | |
| 80306 | <1% | 281 | $4K | |
| 83880 | <1% | 173 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 434 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 744 | $4K |
| 87186 | <1% | 427 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 59 | $3K |
| 85379 | <1% | 288 | $3K | |
| 87040 | <1% | 218 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 939 | $3K |
| 86140 | <1% | 370 | $2K | |
| 84481 | <1% | 180 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 86 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,049 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 51 | $2K |
| 85610 | <1% | 489 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 342 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 44 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 27 | $2K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 151 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 62 | $2K |
| 73630 | <1% | 111 | $1K | |
| 86850 | <1% | 183 | $1K | |
| 74018 | <1% | 69 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 515 | $1K |
| 73610 | <1% | 72 | $1K | |
| 87420 | <1% | 79 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $1K |
| 86901 | <1% | 306 | $958.48 | |
| 73564 | <1% | 36 | $814.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 290 | $801.40 |
| 86900 | <1% | 247 | $770.46 | |
| 73110 | <1% | 40 | $726.20 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 191 | $716.73 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17 | $699.92 |
| 85652 | <1% | 133 | $699.72 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 13 | $663.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 61 | $641.34 |
| 86593 | <1% | 132 | $587.98 | |
| 36416 | <1% | 209 | $579.65 | |
| 86703 | <1% | 43 | $578.73 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 46 | $560.97 |
| 82728 | <1% | 50 | $530.25 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 163 | $500.83 |
| 84703 | <1% | 55 | $483.65 | |
| 82607 | <1% | 37 | $476.36 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 44 | $472.05 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 306 | $458.30 |
| 87210 | <1% | 96 | $447.90 | |
| 83735 | <1% | 80 | $402.19 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 32 | $402.18 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 61 | $262.07 |
| 87340 | <1% | 28 | $252.54 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $243.26 |
| 86803 | <1% | 13 | $198.28 | |
| 90715 | <1% | 13 | $185.70 | |
| 86762 | <1% | 13 | $143.91 | |
| 72100 | <1% | 12 | $136.22 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $128.59 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 158 | $104.78 |
| 81002 | <1% | 44 | $88.54 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 627 | $70.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13 | $60.90 |
| G0008 | Administration of influenza virus vaccine | <1% | 54 | $45.07 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 74 | $37.50 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 667 | $0.03 |
| A9270 | Non-covered item or service | 0% | 376 | $0.00 |
| 80050 | General health panel | 0% | 35 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 42 | $-7.43 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Clinic-Treasure Valley LLC | Boise, ID | $59.26M |
| ST Luke's Clinic LLC | Twin Falls, ID | $39.50M |
| ST Lukes Regional Medical Center | Boise, ID | $24.98M |
| ST. Luke's Magic Valley Regional Medical Center, LTD. | Twin Falls, ID | $7.95M |
| ST Lukes Clinic-Treasure Valley LLC | Mountain Home, ID | $6.86M |
| Magic Valley Paramedics L L C | Twin Falls, ID | $4.57M |
| ST Lukes Clinic-Treasure Valley LLC | Baker City, OR | $2.08M |
| ST Lukes Nampa Medical Center LTD | Nampa, ID | $1.87M |
| ST Luke's Regional Medical Center | Meridian, ID | $1.55M |
| ST Lukes Clinic - Wood River LLC | Ketchum, ID | $717K |
| ST Luke's Magic Valley Regional Medical Center LTD | Jerome, ID | $577K |
| ST Lukes Clinic - Mccall LLC | Mccall, ID | $576K |
| ST Luke's Regional Medical Center | Meridian, ID | $397K |
| ST. Luke's Magic Valley Regional Medical Center LTD | Twin Falls, ID | $300K |
| ST Lukes Wood River Medical Center LTD | Ketchum, ID | $174K |
| ST Lukes Mccall LTD | Mccall, ID | $149K |
| ST Lukes Regional Medical Center | Boise, ID | $49K |
| ST Lukes Magic Valley Regional Medical Center LTD | Twin Falls, ID | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.